R&D investments of listed pharmaceutical companies remain unchanged
R&D investments of listed pharmaceutical companies have remained unchanged.
According to the analysis result of 3rd quarter’s performance reports of KOSPI and KOSDAQ listed pharmaceutical companies in 2015, the ratio of R&D investments to sales was 8.1%.
Although the ratio to sales was narrowly...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
